Wheeldon TU et al. |
Helicobacter pylori eradication and peptic ulcer healing: the impact of deleting the proton pump inhibitor and using a once-daily treatment. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12848630
|
Labenz J et al. |
One-week triple therapy with omeprazole, amoxycillin and either clarithromycin or metronidazole for cure of Helicobacter pylori infection. |
1996 |
Aliment. Pharmacol. Ther. |
pmid:8730252
|
Cardenas VM et al. |
Rabeprazole containing triple therapy to eradicate Helicobacter pylori infection on the Texas-Mexican border. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:16393310
|
Bühling A et al. |
Influence of anti-Helicobacter triple-therapy with metronidazole, omeprazole and clarithromycin on intestinal microflora. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11552917
|
Neri M et al. |
Role of antibiotic sensitivity testing before first-line Helicobacter pylori eradication treatments. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:14535876
|
Hokari K et al. |
Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11552922
|
Lai KC et al. |
Lansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in nonsteroidal anti-inflammatory drug users--a randomized trial. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:14535877
|
Kamberoglou D et al. |
Comparison of 1-week vs. 2- or 4-week therapy regimens with ranitidine bismuth citrate plus two antibiotics for Helicobacter pylori eradication. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11552924
|
Harris A |
The importance of clarithromycin dose in the management of H. pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10594406
|
al-Assi MT et al. |
Clarithromycin-amoxycillin therapy for Helicobacter pylori infection. |
1994 |
Aliment. Pharmacol. Ther. |
pmid:7986970
|
Neri M et al. |
Omeprazole, bismuth and clarithromycin in the sequential treatment of Helicobacter pylori infection. |
1994 |
Aliment. Pharmacol. Ther. |
pmid:7986974
|
Okudaira K et al. |
Concomitant dosing of famotidine with a triple therapy increases the cure rates of Helicobacter pylori infections in patients with the homozygous extensive metabolizer genotype of CYP2C19. |
2005 |
Aliment. Pharmacol. Ther. |
pmid:15710002
|
Lai KC et al. |
Effect of treatment of Helicobacter pylori on the prevention of gastroduodenal ulcers in patients receiving long-term NSAIDs: a double-blind, placebo-controlled trial. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12641502
|
Zullo A et al. |
High eradication rates of Helicobacter pylori with a new sequential treatment. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12641522
|
Wong BC et al. |
Comparison of lansoprazole-based triple and dual therapy for treatment of Helicobacter pylori-related duodenal ulcer: an Asian multicentre double-blind randomized placebo controlled study. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10651663
|
Lane JA et al. |
Randomised clinical trial: Helicobacter pylori eradication is associated with a significantly increased body mass index in a placebo-controlled study. |
2011 |
Aliment. Pharmacol. Ther. |
pmid:21366634
|
Fock KM et al. |
Triple therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer disease: results of a multicentre study in South-East Asia. South-East Asia Multicenter Study Group. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10651664
|
Katelaris PH et al. |
A randomized prospective comparison of clarithromycin versus amoxycillin in combination with omeprazole for eradication of Helicobacter pylori. |
1995 |
Aliment. Pharmacol. Ther. |
pmid:7605864
|
Yousfi MM et al. |
Metronidazole, omeprazole and clarithromycin: an effective combination therapy for Helicobacter pylori infection. |
1995 |
Aliment. Pharmacol. Ther. |
pmid:7605865
|
Sheu BS et al. |
Impact of intravenous omeprazole on Helicobacter pylori eradication by triple therapy in patients with peptic ulcer bleeding. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11856088
|
Choi IJ et al. |
Efficacy of low-dose clarithromycin triple therapy and tinidazole-containing triple therapy for Helicobacter pylori eradication. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11856089
|
Bazzoli F et al. |
Low-dose lansoprazole and clarithromycin plus metronidazole vs. full-dose lansoprazole and clarithromycin plus amoxicillin for eradication of Helicobacter pylori infection. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11856090
|
Barth J and Hahne W |
Review article: rabeprazole-based therapy in Helicobacter pylori eradication. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11849125
|
Qasim A and O'Morain CA |
Review article: treatment of Helicobacter pylori infection and factors influencing eradication. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11849124
|
Calvet X et al. |
Two-week dual vs. one-week triple therapy for cure of Helicobacter pylori infection in primary care: a multicentre, randomized trial. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10383508
|
Sieg A et al. |
Short-term triple therapy with lansoprazole 30 mg or 60 mg, amoxycillin and clarithromycin to eradicate Helicobacter pylori. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10383519
|
Cestari R |
Ranitidine bismuth citrate (RBC) based triple therapy for 7 days is more effective than RBC plus clarithromycin for 14 days in dyspeptic patients with Helicobacter pylori infection. H. Pylori Lombardy Group. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9798804
|
Grimley CE et al. |
Comparison of two 3-day Helicobacter pylori eradication regimens with a standard 1-week regimen. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10383520
|
Spadaccini A et al. |
Triple regimens using lansoprazole or ranitidine bismuth citrate for Helicobacter pylori eradication. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9798805
|
Houben MH et al. |
Randomized trial of omeprazole and clarithromycin combined with either metronidazole or amoxycillin in patients with metronidazole-resistant or -susceptible Helicobacter pylori strains. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10383522
|
Bortolotti M et al. |
Effects of oral clarithromycin and amoxycillin on interdigestive gastrointestinal motility of patients with functional dyspepsia and Helicobacter pylori gastritis. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9798808
|
Gisbert JP and Calvet X |
Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori. |
2011 |
Aliment. Pharmacol. Ther. |
pmid:21745241
|
John Albert M et al. |
High prevalence and level of resistance to metronidazole, but lack of resistance to other antimicrobials in Helicobacter pylori, isolated from a multiracial population in Kuwait. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:17059517
|
Villoria A et al. |
Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. |
2008 |
Aliment. Pharmacol. Ther. |
pmid:18644011
|
Furuta T et al. |
Effect of MDR1 C3435T polymorphism on cure rates of Helicobacter pylori infection by triple therapy with lansoprazole, amoxicillin and clarithromycin in relation to CYP 2C19 genotypes and 23S rRNA genotypes of H. pylori. |
2007 |
Aliment. Pharmacol. Ther. |
pmid:17697203
|
Veldhuyzen Van Zanten S et al. |
One-week triple therapy with esomeprazole provides effective eradication of Helicobacter pylori in duodenal ulcer disease. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:11121908
|
Kim YS et al. |
Randomised clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for Helicobacter pylori in Korea. |
2011 |
Aliment. Pharmacol. Ther. |
pmid:21923713
|
Leiper K et al. |
Clinical trial: randomized study of clarithromycin versus placebo in active Crohn's disease. |
2008 |
Aliment. Pharmacol. Ther. |
pmid:18315579
|
Thung I et al. |
Review article: the global emergence of Helicobacter pylori antibiotic resistance. |
2016 |
Aliment. Pharmacol. Ther. |
pmid:26694080
|
Gisbert JP et al. |
Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:11012477
|
Ford AC et al. |
Clinical trial: knowledge of negative Helicobacter pylori status reduces subsequent dyspepsia-related resource use. |
2007 |
Aliment. Pharmacol. Ther. |
pmid:17944741
|
Graham DY et al. |
Ranitidine bismuth citrate, tetracycline, clarithromycin twice-a-day triple therapy for clarithromycin susceptible Helicobacter pylori infection. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10102946
|
Zanten SJ et al. |
The DU-MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10102960
|
Janssen MJ et al. |
A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11328254
|
Tankovic J et al. |
Impact of Helicobacter pylori resistance to clarithromycin on the efficacy of the omeprazole-amoxicillin-clarithromycin therapy. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11328266
|
Higuchi K et al. |
Is eradication sufficient to heal gastric ulcers in patients infected with Helicobacter pylori? A randomized, controlled, prospective study. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12492739
|
Coelho LG et al. |
Once-daily, low-cost, highly effective Helicobacter pylori treatment to family members of gastric cancer patients. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12492742
|
Feydt-Schmidt A et al. |
Fluorescence in situ hybridization vs. epsilometer test for detection of clarithromycin-susceptible and clarithromycin-resistant Helicobacter pylori strains in gastric biopsies from children. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:12452940
|
Zullo A et al. |
Primary antibiotic resistance in Helicobacter pylori strains isolated in northern and central Italy. |
2007 |
Aliment. Pharmacol. Ther. |
pmid:17539982
|
Nista EC et al. |
Bacillus clausii therapy to reduce side-effects of anti-Helicobacter pylori treatment: randomized, double-blind, placebo controlled trial. |
2004 |
Aliment. Pharmacol. Ther. |
pmid:15569121
|